Articles related to NEOADJUVANT TREATMENT

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.

New data suggests that intensifying neoadjuvant therapy with abiraterone or docetaxel could significantly improve outcomes in very high-risk prostate cancer patients. Explore the full findings to consider how this could impact your treatment approach.

Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.

Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway